Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Later, Wacław Szybalski popularized the term in 1974 in reference to genetic engineering, but little did he know that one day ...

The obesity treatment market is projected to reach $206.5bn by 2031, as per GlobalData. Credit: Cunaplus_M.Faba via Getty Images. Novo Nordisk has signed a deal worth up to $1bn with Lexicon ...

The agreement grants Jumpcode access to ERS' CRISPR/Cas9 patent portfolio, empowering the company to advance the sensitivity and efficiency of next-generation sequencing (NGS) and expand applications ...

The agreement grants Jumpcode access to ERS' CRISPR/Cas9 patent portfolio, empowering the company to advance the sensitivity and efficiency of next-generation sequencing (NGS) and expand ...

With a portfolio of 100+ patents worldwide, ERS' IP covers CRISPR/Cas9 applications across all cell types, including mammalian cells, bacteria, archaea, yeasts, and algae, as well as extracellular ...

CRISPR Therapeutics' shares are down by 41% ... into Keytruda's market share -- and the older medicine will run out of patent exclusivity in 2028. Last year, Merck generated revenue of $64.2 ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR ...